Cargando…
Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
Pancreatic ductal adenocarcinoma (PDAC) correlates with high mortality and is about to become one of the major reasons for cancer-related mortality in the next decades. One reason for that high mortality is the limited availability of effective chemotherapy as well as the intrinsic or acquired resis...
Autores principales: | Braun, Lukas M., Lagies, Simon, Guenzle, Jessica, Fichtner-Feigl, Stefan, Wittel, Uwe A., Kammerer, Bernd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290296/ https://www.ncbi.nlm.nih.gov/pubmed/32438599 http://dx.doi.org/10.3390/cells9051251 |
Ejemplares similares
-
Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures
por: Braun, Lukas M., et al.
Publicado: (2020) -
nab-Paclitaxel for the treatment of pancreatic cancer
por: Kim, George
Publicado: (2017) -
Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong, Yuan, et al.
Publicado: (2020) -
Surgical pancreatic biopsies for cases with locally advanced pancreatic cancer with inconclusive histology after interventional biopsy
por: Klösges, Laura, et al.
Publicado: (2023) -
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
por: Corrie, P. G., et al.
Publicado: (2020)